NO158740C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser. - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser.

Info

Publication number
NO158740C
NO158740C NO841158A NO841158A NO158740C NO 158740 C NO158740 C NO 158740C NO 841158 A NO841158 A NO 841158A NO 841158 A NO841158 A NO 841158A NO 158740 C NO158740 C NO 158740C
Authority
NO
Norway
Prior art keywords
substituted
preparation
therapeutically active
azetidinone compounds
analogy procedure
Prior art date
Application number
NO841158A
Other languages
English (en)
Other versions
NO158740B (no
NO841158L (no
Inventor
Toshinari Tamura
Hidenori Iwamoto
Makoto Yoshida
Minoru Yamamoto
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP58048989A external-priority patent/JPS59225182A/ja
Priority claimed from JP58221470A external-priority patent/JPS60115578A/ja
Priority claimed from JP58221469A external-priority patent/JPS60115577A/ja
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO841158L publication Critical patent/NO841158L/no
Priority to NO870289A priority Critical patent/NO167662C/no
Publication of NO158740B publication Critical patent/NO158740B/no
Publication of NO158740C publication Critical patent/NO158740C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO841158A 1983-03-25 1984-03-23 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser. NO158740C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO870289A NO167662C (no) 1983-03-25 1987-01-23 4-substituerte-2-azetidinonforbindelser.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP58048989A JPS59225182A (ja) 1983-03-25 1983-03-25 ２−アゼチジノン−４−カルボン酸の誘導体
JP58221470A JPS60115578A (ja) 1983-11-25 1983-11-25 ２−アゼチジノン−４−置換化合物
JP58221469A JPS60115577A (ja) 1983-11-25 1983-11-25 ２−アゼチジノン−４−置換体

Publications (3)

Publication Number Publication Date
NO841158L NO841158L (no) 1984-09-26
NO158740B NO158740B (no) 1988-07-18
NO158740C true NO158740C (no) 1988-10-26

Family

ID=27293483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841158A NO158740C (no) 1983-03-25 1984-03-23 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser.

Country Status (8)

Country Link
US (3) US4564609A (no)
EP (1) EP0123444B1 (no)
KR (3) KR870000357B1 (no)
CA (1) CA1256650A (no)
DE (1) DE3476399D1 (no)
DK (1) DK164684A (no)
ES (4) ES530960A0 (no)
NO (1) NO158740C (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719207A (en) * 1984-06-25 1988-01-12 Yamanouchi Pharmaceutical Co., Ltd. CNS active substituted azetidinone compounds
JPS6253994A (ja) 1985-05-09 1987-03-09 Yamanouchi Pharmaceut Co Ltd １−置換シリル−４−オキソ−２−アゼチジンカルボン酸低級アルキルエステル
ZA868957B (en) * 1985-12-06 1987-07-29 Yamanouchi Pharma Co Ltd Crystals of nalpha-(((s)-4-oxo-2-azetidinyl)carbonyl)-l-histidyl-l-prolinamide and process for producing the crystals
US5686420A (en) * 1987-06-05 1997-11-11 Georgetown University Thyrotropin-releasing hormone analogs and method of use
US5151497A (en) * 1989-02-21 1992-09-29 Japan Tobacco Inc. Histidyl peptide derivatives
DK437289D0 (da) * 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
IT1249728B (it) * 1991-11-06 1995-03-09 Sigma Tau Ind Farmaceuti Derivati delle prolinammide quali attivatori della memoria e dei processi di apprendimento e composizioni farmaceutiche che li contengono
JP2001524132A (ja) * 1997-05-09 2001-11-27 スミスクライン・ビーチャム・コーポレイション ＣｏＡ−ＩＴのベータ−ラクタム阻害剤
US20020151502A1 (en) * 1997-10-09 2002-10-17 Albert Sattin Tri-peptides for neurological and neurobehavior applications
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
US20030175350A1 (en) * 2000-07-11 2003-09-18 Katsuji Sugita Enteric preparations containing physiologically active peptides
US7129256B2 (en) 2000-08-31 2006-10-31 Shionogi & Co., Ltd. Antiparkinsonism drugs
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2434430A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2002058731A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DE60216890T2 (de) * 2001-01-26 2007-08-30 Schering Corp. Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1392287B8 (en) * 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DK1427409T3 (da) * 2001-09-21 2009-01-12 Schering Corp Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja) * 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CA2517573C (en) * 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7208486B2 (en) * 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
KR101137503B1 (ko) * 2009-07-14 2012-04-20 웰이앤씨 주식회사 고분자 고체 지지체를 이용한 히스티딜-프롤린아미드 유도체의 제조 방법
PL3033316T3 (pl) * 2013-08-16 2021-01-25 Triad National Security, Llc Związki i sposoby do poprawy wydajności roślin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959248A (en) * 1974-04-03 1976-05-25 Merck & Co., Inc. Analogs of thyrotropin-releasing hormone
GB1523598A (en) * 1975-03-08 1978-09-06 Reckitt & Colmann Prod Ltd Tripeptides
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
HU180926B (en) * 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for preparing trh analogues,tripeptide amides infectives on the central nerve sysrhem
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Also Published As

Publication number Publication date
DK164684D0 (da) 1984-03-23
DE3476399D1 (en) 1989-03-02
ES8600279A1 (es) 1985-10-01
KR870000357B1 (ko) 1987-03-05
EP0123444B1 (en) 1989-01-25
CA1256650A (en) 1989-06-27
ES8604136A1 (es) 1986-01-16
ES8604208A1 (es) 1986-01-16
US4610821A (en) 1986-09-09
KR840008021A (ko) 1984-12-12
ES544236A0 (es) 1986-01-16
NO158740B (no) 1988-07-18
KR880009549A (ko) 1988-09-15
ES544234A0 (es) 1986-01-16
KR880009550A (ko) 1988-09-15
DK164684A (da) 1984-09-26
ES544235A0 (es) 1986-01-16
ES530960A0 (es) 1985-10-01
ES8604209A1 (es) 1986-01-16
KR890002105B1 (ko) 1989-06-19
KR890002104B1 (ko) 1989-06-19
EP0123444A1 (en) 1984-10-31
US4636567A (en) 1987-01-13
NO841158L (no) 1984-09-26
US4564609A (en) 1986-01-14

Similar Documents

Publication Publication Date Title
NO158740C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-substituerte 2-azetidinonforbindelser.
NO161065C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-azetidinoner.
NO160521C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 13alfa- alkylgonaner.
NO163691C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-acryl-piperazinalkanamider.
NO159089C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive glutarimidderivater.
NO170977C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aryl-piperazinyl-etyl (eller butyl)-heterocykliske forbindelser
NO158540C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-penem-forbindelser.
NO162858C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive thiazolidinderivater.
NO152904C (no) Analogifremgangsmaate til fremstilling av farmakologisk virksomme heksapyranoseforbindelser.
NO158060C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonforbindelser.
NO166083C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyridazodiazepinderivater.
NO164472C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte 2-(monokondenserte (3,4- og 5,6)-pyridylalkylensulfinyl)-benzimidazoler.
NO158534C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenoksyalkylkarboksylsyrederivater.
NO153370C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive, stabile s-adenosylmethionisalter.
NO159930C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indeno-pyridazinon-derivater.
NO165400C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cefemforbindelser.
NO165842C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO158673C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive azurenderivater.
NO163330C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive isokinolinderivater.
NO164415C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5-acyl-2-(1h)-pyridinoner.
NO167923C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptidsubstituerte heterocykliske forbindelser
NO158376C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme rooperolforbindelser.
NO156865B (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme imidazolderivater.
NO161800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-(2-aryl-2-halo-1-etenyl)-1h-azoler.